Hearing Loss Trial, Recruiting NCT07017998 Sponsor: Restorear Devices LLC Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT07017998
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 55 at the time of signing the consent form whose main concern is tinnitus (ringing or noise in the ears)
  • People who have been experiencing tinnitus for at least 30 days
  • People whose tinnitus scores at least 12 on a standard tinnitus severity questionnaire called the Tinnitus Handicap Inventory (THI)
  • People whose tinnitus is present during at least 75% of waking hours (considered constant rather than occasional)

Who may not be able to join:

  • People whose tinnitus scores below 12 on the THI questionnaire, indicating very mild tinnitus
  • People whose tinnitus comes and goes rather than being present most of the time
  • People whose tinnitus is pulsatile (beats in time with the heartbeat) or is not sound-based in nature
  • People with a history of vertigo or fluctuating hearing loss, including conditions such as Menière's disease, chronic ear infections, vestibular neuritis, acoustic neuroma, otosclerosis, cholesteatoma, or jaw joint (TMJ) disorders
  • People with a history of extreme sensitivity to cold or heat, including those who have experienced frostbite or Raynaud's Syndrome
  • People currently receiving any treatment for tinnitus or other ear conditions, including sound therapy, cognitive behavioural therapy (CBT), Tinnitus Retraining Therapy (TRT), steroid injections, or similar treatments
  • People whose responses to a standard mental health screening questionnaire (PHQ-4) indicate moderate to severe anxiety or depression
  • People under 18 years of age, incarcerated individuals, adults who are unable to give consent, or those considered psychologically vulnerable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Suhrud Rajguru, PhD, RestorEar Devices

Phone: 2068187219

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Restorear Devices LLC
Registry
ClinicalTrials.gov
Start date
16 July 2025
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Subjective Tinnitus Severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov